Delamanid-containing regimens and multidrug-resistant tuberculosis: A systematic review and meta-analysis

Tuberculosis and COVID-19 interaction: a review of biological, clinical and public health effects

(2021) D. Visca et al.   Pulmonology

QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial

(2021) Kelly E Dooley et al.   LANCET INFECTIOUS DISEASES

New definitions of pre-extensively and extensively drug-resistant tuberculosis: update from the World Health Organization

(2021) Kerri Viney et al.   EUROPEAN RESPIRATORY JOURNAL

Outcome of treatment of MDR-TB or drug-resistant patients treated with bedaquiline and delamanid: Results from a large global cohort

(2021) S. Koirala et al.   Pulmonology

Treatment success using novel and adapted treatment regimens in registered DR-TB children in Dushanbe, Tajikistan, 2013-2019

(2021) Bobojon Pirmahmadzoda et al.   Journal of Infection in Developing Countries

MDR/XDR-TB management of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network

(2020) Giovanni Battista Migliori et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Bedaquiline and Delamanid in Children With XDR Tuberculosis

(2020) Ira Shah et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases

(2020) Marina Tadolini et al.   EUROPEAN RESPIRATORY JOURNAL

Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid

(2020) Suha Kadura et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Tuberculosis, COVID-19 and migrants: Preliminary analysis of deaths occurring in 69 patients from two cohorts

(2020) I. Motta et al.   Pulmonology

Delamanid resistance: update and clinical management

(2020) Thi Van Anh Nguyen et al.   CLINICAL INFECTIOUS DISEASES

Long-term safety and tolerability of delamanid-containing regimens in MDR- and XDR-TB patients in a specialised tuberculosis treatment center in Berlin, Germany

(2020) Brit Häcker et al.   EUROPEAN RESPIRATORY JOURNAL

Correspondence regarding “Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa”

(2020) Erika Mohr-Holland et al.   EUROPEAN RESPIRATORY JOURNAL

Interim treatment outcomes in multidrug-resistant tuberculosis using bedaquiline and/or delamanid in South Korea

(2020) Hyungseok Kang et al.   RESPIRATORY MEDICINE

Population Pharmacokinetic Analysis of Delamanid in Patients with Pulmonary Multi-Drug Resistant Tuberculosis

(2020) Xiaofeng Wang et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

One step forward: Successful end-of-treatment outcomes of drug-resistant TB patients who received concomitant bedaquiline and delamanid in Mumbai, India

(2020) Mrinalini Das et al.   CLINICAL INFECTIOUS DISEASES

Concurrent Use of Bedaquiline and Delamanid for the Treatment of Fluoroquinolone-resistant Multidrug-resistant Tuberculosis: A Nationwide Cohort Study in South Korea

(2020) Yong-Soo Kwon et al.   EUROPEAN RESPIRATORY JOURNAL

Interim treatment outcomes in multidrug-resistant tuberculosis patients treated sequentially with bedaquiline and delamanid

(2020) Hoon Hee Lee et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Compassionate Use of Delamanid in Adults and Children for Drug-resistant TB: 5-year Update

(2020) Sambuddha Ghosh et al.   EUROPEAN RESPIRATORY JOURNAL

New TB drugs for the treatment of children and adolescents with rifampicin-resistant TB in Mumbai, India

(2020) M. Das et al.   INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE

Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial

(2019) Florian von Groote-Bidlingmaier et al.   Lancet Respiratory Medicine

Final treatment outcomes of delamanid-containing regimens in patients with MDR-/XDR-TB in South Korea

(2019) Jeongha Mok et al.   EUROPEAN RESPIRATORY JOURNAL

Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline

(2019) Payam Nahid et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

A regimen containing bedaquiline and delamanid compared to bedaquiline in patients with drug resistant tuberculosis

(2019) Olatunde Olayanju et al.   EUROPEAN RESPIRATORY JOURNAL

Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report

(2019) Sergey Borisov et al.   EUROPEAN RESPIRATORY JOURNAL

Bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis: a multicentre cohort study in Korea

(2018) Cheon Tae Kim et al.   EUROPEAN RESPIRATORY JOURNAL

Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa

(2018) Erika Mohr et al.   EUROPEAN RESPIRATORY JOURNAL

Early experience with delamanid-containing regimens in the treatment of complicated multidrug-resistant tuberculosis in Hong Kong

(2018) Kwok-Chiu Chang et al.   EUROPEAN RESPIRATORY JOURNAL

Combined treatment of drug-resistant tuberculosis with bedaquiline and delamanid: a systematic review

(2018) Emanuele Pontali et al.   EUROPEAN RESPIRATORY JOURNAL

Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study

(2018) Gabriella Ferlazzo et al.   LANCET INFECTIOUS DISEASES

Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis

(2018) Elizabeth P. Harausz et al.   PLOS MEDICINE

Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis

(2018) Nafees Ahmad et al.   LANCET

Compassionate use of delamanid in combination with bedaquiline for the treatment of multidrug-resistant tuberculosis

(2018) Jeffrey Hafkin et al.   EUROPEAN RESPIRATORY JOURNAL

Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study

(2017) Sergey E. Borisov et al.   EUROPEAN RESPIRATORY JOURNAL

Final treatment outcomes of multidrug- and extensively drug-resistant tuberculosis patients in Latvia receiving delamanid-containing regimens

(2017) Liga Kuksa et al.   EUROPEAN RESPIRATORY JOURNAL

Early outcomes in MDR-TB and XDR-TB patients treated with delamanid under compassionate use

(2017) Jeffrey Hafkin et al.   EUROPEAN RESPIRATORY JOURNAL

Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review

(2017) Giovanni Migliori et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Delamanid and bedaquiline to treat multidrug-resistant and extensively drug-resistant tuberculosis in children: a systematic review

(2017) Lia D’Ambrosio et al.   Journal of Thoracic Disease

Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis: early experiences and challenges

(2016) Marina Tadolini et al.   EUROPEAN RESPIRATORY JOURNAL

Long-term mortality assessment of multidrug-resistant tuberculosis patients treated with delamanid: TABLE 1

(2015) Charles D. Wells et al.   EUROPEAN RESPIRATORY JOURNAL

ERS/WHO Tuberculosis Consilium assistance with extensively drug-resistant tuberculosis management in a child: case study of compassionate delamanid use

(2014) S. Esposito et al.   EUROPEAN RESPIRATORY JOURNAL

Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis

(2012) Vija Skripconoka et al.   EUROPEAN RESPIRATORY JOURNAL

Delamanid for Multidrug-Resistant Pulmonary Tuberculosis

(2012) Maria Tarcela Gler et al.   NEW ENGLAND JOURNAL OF MEDICINE

Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients

(2011) A. H. Diacon et al.   INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

(2009) David Moher et al.   PLOS MEDICINE